Compare Stocks

→ The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACUS Acusphere		$0.00	$0.00 ▼ $0.05	N/A	-1.31	14 shs	N/A
AFFY Affymax	$0.00	$0.00	$0.00 ▼ $0.04	N/A	6.01	21,900 shs	700 shs
ALSE Alseres Pharmaceuticals	$0.01	$0.01	$0.01 ▼ $0.01	N/A	0.13	N/A	N/A
BOPH Bohai Pharmaceuticals Group	$0.00	$0.00	$0.00 ▼ $0.00	$20K	1.78	30,425 shs	50,000 shs
IMUN Immune Therapeutics	$0.09	$0.09	$0.07 ▼ $1.30	$7.78M	0.46	15,246 shs	12 shs

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACUS Acusphere	0.00%	0.00%	0.00%	0.00%	0.00%
AFFY Affymax	0.00%	0.00%	0.00%	0.00%	-82.93%
ALSE Alseres Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-50.00%
BOPH Bohai Pharmaceuticals Group	0.00%	0.00%	0.00%	0.00%	0.00%
IMUN Immune Therapeutics	0.00%	0.00%	0.00%	0.00%	-84.50%

$21,000 in profits in six weeks? (Ad)

On Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges.

Click here for details.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACUS Acusphere	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AFFY Affymax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ALSE Alseres Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BOPH Bohai Pharmaceuticals Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMUN Immune Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACUS Acusphere	N/A	N/A	N/A	N/A
AFFY Affymax	N/A	N/A	N/A	N/A
ALSE Alseres Pharmaceuticals	N/A	N/A	N/A	N/A
BOPH Bohai Pharmaceuticals Group	N/A	N/A	N/A	N/A
IMUN Immune Therapeutics	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACUS Acusphere	N/A	N/A	N/A	N/A	N/A	N/A
AFFY Affymax	N/A	N/A	N/A	N/A	N/A	N/A
ALSE Alseres Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
BOPH Bohai Pharmaceuticals Group	N/A	N/A	N/A	N/A	N/A	N/A
IMUN Immune Therapeutics	N/A	N/A	N/A	N/A	($0.03) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACUS Acusphere	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AFFY Affymax	N/A	N/A	∞	N/A	N/A	N/A	N/A	N/A
ALSE Alseres Pharmaceuticals	N/A	N/A	∞	N/A	N/A	N/A	N/A	N/A
BOPH Bohai Pharmaceuticals Group	N/A	N/A	∞	N/A	N/A	N/A	N/A	N/A
IMUN Immune Therapeutics	-$3.54M	N/A	∞	N/A	N/A	N/A	-544.75%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACUS Acusphere	N/A	N/A	N/A	N/A	N/A
AFFY Affymax	N/A	N/A	N/A	N/A	N/A
ALSE Alseres Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BOPH Bohai Pharmaceuticals Group	N/A	N/A	N/A	N/A	N/A
IMUN Immune Therapeutics	N/A	N/A	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
ACUS Acusphere	N/A
AFFY Affymax	N/A
ALSE Alseres Pharmaceuticals	N/A
BOPH Bohai Pharmaceuticals Group	N/A
IMUN Immune Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ACUS Acusphere	4.60%
AFFY Affymax	1.55%
ALSE Alseres Pharmaceuticals	8.94%
BOPH Bohai Pharmaceuticals Group	N/A
IMUN Immune Therapeutics	50.59%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ACUS Acusphere	118	N/A	N/A	Not Optionable
AFFY Affymax	2	N/A	N/A	Not Optionable
ALSE Alseres Pharmaceuticals	3	N/A	N/A	Not Optionable
BOPH Bohai Pharmaceuticals Group	N/A	19.52 million	N/A	Not Optionable
IMUN Immune Therapeutics	2	83.66 million	41.34 million	Not Optionable

ALSE, BOPH, IMUN, ACUS, and AFFY Headlines

Source	Headline
	Researchers find B cells drive responses of other immune cells, can be modified to prevent multiple sclerosis symptoms msn.com - May 7 at 8:12 AM
	Hacking the immune system could slow ageing — here’s how nature.com - May 7 at 8:12 AM
	Critical Analysis: Vincerx Pharma (NASDAQ:VINC) vs. Immune Therapeutics (OTCMKTS:IMUN) americanbankingnews.com - May 4 at 1:34 AM
	ImmuneSensor Therapeutics Announces New President/CEO dallasinnovates.com - May 3 at 8:13 PM
	Researchers discover how immune B cells hunt down cancer around the body msn.com - May 2 at 7:08 PM
	Controlled human infection study paves the way to improving vaccines and therapeutics development msn.com - May 2 at 2:08 PM
	Repertoire Immune Medicines, Bristol Myers Squibb enter collaboration to develop tolerizing vaccines for autoimmune diseases pharmabiz.com - April 30 at 4:33 AM
	Immune key to chronic viral infections discovered sciencedaily.com - April 29 at 11:32 PM
	Repertoire Immune Medicines In Strategic Partnership With Bristol Myers Squibb markets.businessinsider.com - April 29 at 8:22 AM
	Harnessing immune enhancement to combat drug-resistant tuberculosis news-medical.net - April 28 at 3:20 PM
	Experts developing immune-enhancing therapies to target tuberculosis eurekalert.org - April 27 at 3:09 AM
	Experts develop immune-enhancing therapies to target tuberculosis msn.com - April 26 at 10:08 PM
	EXCLUSIVE: Virax Biolabs Launches Immune Profiling Solutions To Evaluate Adaptive Immunity In Post-Viral Syndromes benzinga.com - April 25 at 8:44 AM
	Supreme Court Will Decide Whether Trump Is Immune From Federal Prosecution. Here's What's Next msn.com - April 22 at 9:41 PM
	Kaspersky Thin Client 2.0: Cyber Immune protection with enhanced connectivity, performance and design zawya.com - April 18 at 1:28 PM
	Immune Boosters Encore on April 21 clearwaterprogress.com - April 18 at 1:54 AM
	Improving drug development with a vast map of the immune system sciencex.com - April 12 at 2:02 PM
	These Stocks Are Moving the Most Today: Alpine Immune, CarMax, Robinhood, Fastenal, Nike, Constellation Brands, and More msn.com - April 11 at 9:43 AM
	Buy Rating Affirmed for Alpine Immune Sciences Amid Positive Clinical Trial Results markets.businessinsider.com - April 8 at 1:55 PM
	Rogue immune cell that can cause poor antibody responses in chronic viral infections discovered msn.com - April 8 at 1:55 PM
	Immune tolerance induction results don’t vary among races, ethnicities hemophilianewstoday.com - April 5 at 2:22 PM
	Immunis Discusses with Experts Why the Immune System is the Key to Human Healthspan finance.yahoo.com - April 5 at 2:22 PM
	Immune Ready program aims to improve productivity, profitability beefcentral.com - April 5 at 4:21 AM
	Immune Boosters Encore is April 7 clearwaterprogress.com - April 4 at 8:15 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acusphere

OTCMKTS:ACUS

Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.

Affymax

OTCMKTS:AFFY

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

Alseres Pharmaceuticals

OTCMKTS:ALSE

Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

Bohai Pharmaceuticals Group

OTCMKTS:BOPH

Bohai Pharmaceuticals Group, Inc. engages in the production, manufacture, and distribution of herbal pharmaceuticals based on traditional Chinese medicine. Its products include lung nourishing syrup, tongbi capsules, tongbi tablets, zhuangyuanshenhailong medicinal wine, bazhenyimu cream, fangfengtongsheng granule, and zhengxintai capsules. The company was founded on January 9, 2008 and is headquartered in Yantai, China.

Immune Therapeutics

OTCMKTS:IMUN

Immune Therapeutics, Inc. does not have significant operations. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in October 2014. Immune Therapeutics, Inc. is based in Winter Park, Florida.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial